These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 10987993)

  • 21. Inhibition of pro-cholecystokinin (CCK) sulfation by treatment with sodium chlorate alters its processing and decreases cellular content and secretion of CCK 8.
    Beinfeld MC
    Neuropeptides; 1994 Mar; 26(3):195-200. PubMed ID: 8208365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholecystokinin inhibition of tumor growth and gastrin-stimulated cyclic adenosine 3':5'-monophosphate metabolism in human gastric carcinoma in nude mice.
    Yasui W; Sumiyoshi H; Ochiai A; Tahara E
    Cancer Res; 1986 Feb; 46(2):740-3. PubMed ID: 3000584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
    J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonsulfated cholecystokinins in the small intestine of pigs and rats.
    Agersnap M; Rehfeld JF
    Peptides; 2015 Sep; 71():121-7. PubMed ID: 26206288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of acid formation and stimulation of somatostatin release by cholecystokinin-related peptides in rabbit gastric glands.
    Bengtsson P; Lundqvist G; Nilsson G
    J Physiol; 1989 Dec; 419():765-74. PubMed ID: 2576071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cholecystokinin and 16,16-dimethyl prostaglandin E2 on RNA and DNA of gastric and duodenal mucosa.
    Johnson LR; Guthrie P
    Gastroenterology; 1976 Jan; 70(1):59-65. PubMed ID: 1245285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulfated cholecystokinin octapeptide in the rat: pontomedullary distribution and modulation of the respiratory pattern.
    Ellenberger HH; Smith FM
    Can J Physiol Pharmacol; 1999 Jul; 77(7):490-504. PubMed ID: 10535709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphine-induced excitation of pyramidal neurons is inhibited by cholecystokinin in the CA1 region of the rat hippocampal slice.
    Miller KK; Lupica CR
    J Pharmacol Exp Ther; 1994 Feb; 268(2):753-61. PubMed ID: 8113987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological effects of human gastrin I and II chemically modified at the C-terminal tetrapeptide amide.
    Galleyrand JC; Fulcrand P; Bali JP; Rodriguez M; Magous R; Laur J; Martinez J
    Peptides; 1992; 13(3):519-25. PubMed ID: 1523164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholecystokinin intracerebroventricularly applied stimulates gastric acid secretion.
    Ishikawa T; Osumi Y; Nakagawa T
    Brain Res; 1985 Apr; 333(1):197-9. PubMed ID: 3995287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine inhibits intestinal-phase gastric-acid secretion.
    Yang EY; Nahrwold DL
    Surgery; 1993 Nov; 114(5):915-20. PubMed ID: 8236015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does sulfation of gastrin influence gastric acid secretion in man?
    Cantor P; Petersen MB; Christiansen J; Rehfeld JF
    Scand J Gastroenterol; 1990 Jul; 25(7):739-45. PubMed ID: 2396089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of tyrosine-O-[35S]sulfated cholecystokinin octapeptide from a nonsulfated precursor peptide.
    Nakahara T; Waki M; Uchimura H; Hirano M; Kim JS; Matsumoto T; Nakamura K; Ishibashi K; Hirano H; Shiraishi A
    Anal Biochem; 1986 Apr; 154(1):194-9. PubMed ID: 3706722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCK-58: a novel reagent for studying the regulation of cholecystokinin bioactivity.
    Raybould HE; Reeve JR
    Peptides; 1996; 17(8):1307-11. PubMed ID: 8971924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological activities of synthetic human cholecystokinin-33 of which tyrosine was sulfated by arylsulfotransferase.
    Hagiwara M; Ohuchi E; Hongo K; Oki M; Nakano M; Amemiya M; Morikawa T; Kobashi K
    Chem Pharm Bull (Tokyo); 1990 May; 38(5):1369-72. PubMed ID: 2393964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. II. Solubilization and separation of membrane-bound CCK-8 cleaving enzymes.
    Deschodt-Lanckman M; Bui ND; Koulischer D; Paroutaud P; Strosberg AD
    Peptides; 1983; 4(1):71-8. PubMed ID: 6306618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of sulfated and unsulfated cholecystokinin octapeptide on conditioned feeding behaviour in rats.
    Fekete M; Balázs M; Penke B; Telegdy G
    Peptides; 1981; 2(4):385-8. PubMed ID: 6276866
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis of human des-tryptophan-1,norleucine-12-minigastrin-II and its biological activities.
    Wünsch E; Moroder L; Göhring W; Borin G; Calderan A; Bali JP
    FEBS Lett; 1986 Oct; 206(2):203-7. PubMed ID: 3758347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.